Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ACLX

2 Potential Stocks to Buy From Barchart’s ‘Death Cross’ Indicator

While a security’s short-term moving average dipping below its long-term average warrants caution, this dynamic may also be a contrarian indicator.

Barchart

These Stocks Are Exploding In The November Stock Market Rally

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

Investors Business Daily

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death

The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday.

Investors Business Daily

3 Stocks with Tremendous Growth Potential in 2023

Given the pace and intensity of the Fed’s monetary tightening, there’s a strong likelihood that the U.S. will enter a recession in 2023. However, amid a strong job market and resilient consumer spending, the possibility of a soft landing still stands. Given this backdrop, quality stocks Gilead Sciences (GILD), Coca-Cola…

StockNews.com

The 3 Hottest Biotech Stocks to Own in 2023 and 1 to Avoid

Biotech companies are on track to stay resilient amid a potential economic slowdown due to their inelastic demand and continued breakthroughs. Therefore, it could be wise to invest in fundamentally strong biotech stocks Gilead Sciences (GILD), United Therapeutics (UTHR), and Jazz Pharmaceuticals (JAZZ). On the other hand, Bionano Genomics (BNGO)…

StockNews.com

3 High-Value Stocks to Buy and Hold for a Lifetime

Despite showing signs of cooling, inflation is still well above the Fed’s 2% target. Moreover, January’s strong jobs report may encourage the Fed to raise interest rates even further, keeping the stock market highly volatile in the near term. Amid an uncertain macro environment, it could be wise to buy…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

2 Stocks to Help Jump-Start Your Passive Income in 2023

Despite an inflow of positive macro data, the Fed’s hawkish stance is expected to keep the markets under pressure for the near term. With price fluctuations being the new norm, dividend-paying stocks with solid fundamentals, BHP Group (BHP) and Gilead Sciences (GILD), could help jump-start a solid stream of passive…

StockNews.com

BofA Initiates Arcellx With Buy On Its Novel Therapy Approach

Arcellx (NASDAQ: ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.

Benzinga

CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19

CAR-T company Arcellx Inc (NASDAQ: ACLX) priced its IPO at

Benzinga

People

Jerome Powell

2,649 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Jazz Pharmaceuticals plc

Bluegreen Vacations Holding Corporation

29 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.